Nanotherapeutics' bone void filler receives expanded FDA 510(k) marketing clearance

Nanotherapeutics received expanded 510(k) marketing clearance from the U.S. Food and Drug Administration for use of NanoFUSE DBM in spinal fusion.

NanoFUSE DBM is the company's proprietary bone void filler product. Specifically, it has been cleared for use with autograft as a bone graft extender in the posterolateral spine. It is the first off-the-shelf DBM product containing bioactive glass available for use in an orthopedic clinical setting.

More articles on devices:

Amedica brings on with PCG Advisory as agency of record
OrthoWorx commits $475k on workforce development — 6 initiatives
Mesoblast gets patent for mesenchymal precursor cell technology — 7 thing to know